Apellis Pharmaceuticals Inc. (APLS) Financial Statements (2024 and earlier)

Company Profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments351,185452,414616,259765,083551,801708,553
Cash and cash equivalents351,185452,414616,259765,083551,801584,189
Short-term investments      124,364
Restricted cash and investments1,1141,0861,0851,2751,2731,259
Receivables206,442169,258110,91331,5057,7278,091
Inventory, net of allowances, customer advances and progress billings146,36298,545103,21685,48485,71459,753
Inventory146,36298,545103,21685,48485,71459,753
Prepaid expense38,82044,61734,40436,55936,35030,356
Other current assets22,40830,84726,80934,34936,65823,925
Total current assets:766,331796,767892,686954,255719,523831,937
Noncurrent Assets
Operating lease, right-of-use asset16,74515,48416,72617,85418,74719,522
Property, plant and equipment4,3454,7905,3395,9676,1485,681
Other noncurrent assets1,3091,17582779315,79915,752
Total noncurrent assets:22,39921,44922,89224,61440,69440,955
TOTAL ASSETS:788,730818,216915,578978,869760,217872,892
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities165,322135,281125,216102,745132,48193,877
Accounts payable37,51618,19227,50031,49437,34214,099
Accrued liabilities127,806117,08997,71671,25195,13979,778
Other undisclosed current liabilities82,27150,34949,62135,89935,12921,569
Total current liabilities:247,593185,630174,837138,644167,610115,446
Noncurrent Liabilities
Long-term debt and lease obligation93,03392,95792,88392,80992,736107,950
Long-term debt, excluding current maturities93,03392,95792,88392,80992,73692,663
Liabilities, other than long-term debt13,76611,82612,49513,58014,3521,938
Other liabilities2,312946429347 1,938
Operating lease, liability11,45410,88012,06613,23314,35215,287
Other undisclosed noncurrent liabilities239,817295,532289,960321,713315,647340,142
Total noncurrent liabilities:346,616400,315395,338428,102422,735450,030
Total liabilities:594,209585,945570,175566,746590,345565,476
Equity
Equity, attributable to parent194,521232,271345,403412,123169,872307,416
Common stock121212121111
Additional paid in capital3,035,5392,982,2362,954,8622,899,5242,479,5962,453,301
Accumulated other comprehensive loss(3,542)(1,065)(796)(775)(875)(3,027)
Accumulated deficit(2,837,488)(2,748,912)(2,608,675)(2,486,638)(2,308,860)(2,142,869)
Total equity:194,521232,271345,403412,123169,872307,416
TOTAL LIABILITIES AND EQUITY:788,730818,216915,578978,869760,217872,892

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues146,377110,39994,96944,84622,66322,056
Cost of revenue
(Cost of Goods and Services Sold)
      
Other undisclosed gross profit (6,400)     
Gross profit:139,977110,39994,96944,84622,66322,056
Operating expenses(230,895)(247,479)(215,410)(219,929)(186,716)(174,994)
Other undisclosed operating income6,400     
Operating loss:(84,518)(137,080)(120,441)(175,083)(164,053)(152,938)
Nonoperating income4,7674,3865,9395,1164,3292,908
Investment income, nonoperating4,5484,9896,0025,3934,5752,809
Other nonoperating income (expense)219(603)(63)(277)(246)99
Interest and debt expense  (897)(896)   
Other undisclosed income from continuing operations before equity method investments, income taxes 2,687     
Loss from continuing operations before equity method investments, income taxes:(77,064)(133,591)(115,398)(169,967)(159,724)(150,030)
Other undisclosed loss from continuing operations before income taxes(10,089)(6,413)(6,445)(7,529)(7,738)(40,793)
Loss from continuing operations before income taxes:(87,153)(140,004)(121,843)(177,496)(167,462)(190,823)
Income tax expense (benefit)(1,423)(233)(194)(282)1,471(446)
Loss from continuing operations:(88,576)(140,237)(122,037)(177,778)(165,991)(191,269)
Loss before gain (loss) on sale of properties:(191,269)
Net loss available to common stockholders, diluted:(88,576)(140,237)(122,037)(177,778)(165,991)(191,269)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(88,576)(140,237)(122,037)(177,778)(165,991)(191,269)
Comprehensive loss:(88,576)(140,237)(122,037)(177,778)(165,991)(191,269)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,477)(269)(21)1002,152167
Comprehensive loss, net of tax, attributable to parent:(91,053)(140,506)(122,058)(177,678)(163,839)(191,102)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: